非小细胞肺癌放疗的进展与价值

doi:10.3760/cma.j.issn.1673-422X.2019.04.012

摘要/Abstract

摘要： 随着放疗设备的革新和靶向治疗、免疫治疗的推广应用，放疗在非小细胞肺癌（NSCLC）中的治疗模式和地位也不断改变。对于早期NSCLC，立体定向放疗可能成为手术的替代方法，但最佳分割模式仍需探索；对于可手术的局部晚期NSCLC患者，术后放疗仍存在争议，不可手术的患者同步放化疗后巩固免疫疗法结果令人鼓舞，预防性脑照射并不能改善患者生存。寡转移局部放疗有望延长患者生存期。

关键词: 癌, 非小细胞肺, 放射疗法, 治疗结果, 预后

Abstract: With the innovation of radiotherapy equipment and the promotion of targeted therapy and immunotherapy, the therapeutic mode and status of radiotherapy in non-small cell lung cancer (NSCLC) are constantly changing. For early NSCLC, stereotactic radiotherapy may be an alternative to surgery, but the optimal segmentation model still needs to be explored. As for locally advanced NSCLC, postoperative radiotherapy is still controversial for operable patients, the results of consolidated immunotherapy after concurrent chemoradiotherapy in inoperable patients are encouraging, prophylactic cranial irradiation does not improve survival. Local radiotherapy for patients with oligometastasis is expected to prolong survival.

Key words: Carcinoma, non-small-cell lung, Radiotherapy, Treatment outcome, Prognosis

高照,闫文星,刘林林. 非小细胞肺癌放疗的进展与价值[J]. 国际肿瘤学杂志, 2019, 46(4): 248-252.

Gao Zhao, Yan Wenxing, Liu Linlin. Progress and value of radiotherapy for non-small cell lung cancer[J]. Journal of International Oncology, 2019, 46(4): 248-252.

参考文献

［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018［J］. CA Cancer J Clin, 2018, 68(1): 7-30. DOI: 10.3322/caac.21442. ［2］ Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study［J］. JAMA Oncol, 2017, 3(4): 524-548. DOI: 10.1001/jamaoncol.2016.5688. ［3］ Bristow RG, Alexander B, Baumann M, et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology［J］. Lancet Oncol, 2018, 19(5): e240-e251. DOI: 10.1016/S1470-2045(18)30096-2. ［4］ Timmerman RD, Hu C, Michalski JM, et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage Ⅰ non-small cell lung cancer［J］. JAMA Oncol, 2018, 4(9): 1287-1288. DOI: 10.1001/jamaoncol.2018.1258. ［5］ Timmerman RD, Paulus R, Pass HI, et al. Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 trial［J］. JAMA Oncol, 2018, 4(9): 1263-1266. DOI: 10.1001/jamaoncol.2018.1251. ［6］ Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer: a pooled analysis of two randomised trials［J］. Lancet Oncol, 2015, 16(6): 630-637. DOI: 10.1016/S1470-2045(15)70168-3. ［7］ Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403［J］. Int J Radiat Oncol Biol Phys, 2015, 93(5): 989-996. DOI: 10.1016/j.ijrobp.2015.07.2278. ［8］ Videtic GM, Paulus R, Singh AK, et al. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage Ⅰ peripheral non-small cell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2019, 103(5): 1077-1084. DOI: 10.1016/j.ijrobp.2018.11.051. ［9］ Nyman J, Hallqvist A, Lund JA, et al. SPACE-A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage Ⅰ NSCLC［J］. Radiother Oncol, 2016, 121(1): 1-8. DOI: 10.1016/j.radonc.2016.08.015. ［10］ Haque W, Verma V, Polamraju P, et al. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage nonsmall cell lung cancer［J］. Radiother Oncol, 2018, 129(2): 264-269. DOI: 10.1016/j.radonc.2018.07.008. ［11］ Stam B, Kwint M, Guckenberger M, et al. Subgroup survival analysis in stage Ⅰ-Ⅱ NSCLC patients with a central tumor partly treated with risk-adapted SBRT［J］. Int J Radiat Oncol Biol Phys, 2019, 103(1): 132-141. DOI: 10.1016/j.ijrobp.2018.08.040. ［12］ Roach MC, Robinson CG, DeWees TA, et al. Stereotactic body radiation therapy for central early-stage NSCLC: results of a prospective phase Ⅰ/Ⅱ trial［J］. J Thorac Oncol, 2018, 13(11): 1727-1732. DOI: 10.1016/j.jtho.2018.07.017. ［13］ Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer［J］. Cochrane Database Syst Rev, 2015, (3): CD011430. DOI: 10.1002/14651858.CD011430. ［14］ Murakami S, Saito H, Kondo T, et al. Phase Ⅱ study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer［J］. Cancer Chemother Pharmacol, 2018, 81(1): 81-87. DOI: 10.1007/s00280-017-3460-0. ［15］ Burdett S, Rydzewska L, Tierney J, et al. Postoperative radiotherapy for non-small cell lung cancer［J］. Cochrane Database Syst Rev, 2016, 10: CD002142. DOI: 10.1002/14651858.CD002142.pub4. ［16］ Robinson CG, Patel AP, Bradley JD, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base［J］. J Clin Oncol, 2015, 33(8): 870-876. DOI: 10.1200/JCO.2014.58.5380. ［17］ Wang EH, Corso CD, Rutter CE, et al. Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage Ⅱ and Ⅲ non-small-cell lung cancer［J］. J Clin Oncol, 2015, 33(25): 2727-2734. DOI: 10.1200/JCO.2015.61.1517. ［18］ Herskovic A, Mauer E, Christos P , et al. Role of postoperative radiotherapy in pathologic stage ⅢA (N2) non-small cell lung cancer in a prospective nationwide oncology outcomes database［J］. J Thorac Oncol, 2017, 12(2): 302-313. DOI: 10.1016/j.jtho.2016.09.135. ［19］ Hui Z, Men Y, Kang J, et al. Postoperative radiation therapy improves survivals of resected pathological stage ⅢA-N2 non-small cell lung cancer: a retrospective study of 1 434 cases from a single institution［J］. Int J Radiat Oncol Biol Phys, 2018, 102(3 Suppl): e685. ［20］ Shamp S, Biswas T. Post-operative radiation therapy (PORT) in resected non-small cell lung cancer (NSCLC): an updated population based analysis［J］. J Clin Oncol, 2018, 36(15 Suppl): 8522. DOI: 10.1200/JCO.2018.36.15_suppl.8522. ［21］ Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial［J］. Lancet Respir Med, 2018, 6(11): 863-873. DOI: 10.1016/S2213-2600(18)30277-7. ［22］ Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study［J］. Lancet Oncol, 2018, 19(1): 139-148. DOI: 10.1016/S1470-2045(17)30729-5. ［23］ Pennell NA, Neal JW, Chaft JE, et al. SELECT: a phase Ⅱ trial of adjuvant Erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer［J］. J Clin Oncol, 2019, 37(2): 97-104. DOI: 10.1200/jco.18.00131. ［24］ Huang Q, Li J, Sun Y, et al. Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysis［J］. Chest, 2016, 149(6): 1384-1392. DOI: 10.1016/j.chest.2015.12.017. ［25］ Yuan Y, Huang Q, Gu C, et al. Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated metaanalysis［J］. J Thorac Dis, 2017, 9(12): 5314-5321. DOI: 10.21037/jtd.2017.12.58. ［26］ Bezjak A, Temin S, Franklin G, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American society of clinical oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline［J］. J Clin Oncol, 2015, 33(18): 2100-2105. DOI: 10.1200/JCO.2014.59.2360. ［27］ Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC［J］. N Engl J Med, 2018, 379(24): 2342-2350. DOI: 10.1056/NEJMoa1809697. ［28］ Walraven I, Damhuis RA, Ten Berge MG, et al. Treatment variation of sequential versus concurrent chemoradiotherapy in stage Ⅲ non-small cell lung cancer patients in the Netherlands and Belgium［J］. Clin Oncol (R Coll Radiol), 2017, 29(11): e177-e185. DOI: 10.1016/j.clon.2017.07.012. ［29］ Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up［J］. Ann Oncol, 2014, 25(8): 1462-1474. DOI: 10.1093/annonc/mdu089. ［30］ Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage ⅢA or ⅢB non-small-cell lung cancer (RTOG0617): a randomised, two-by-two factorial phase 3 study［J］. Lancet Oncol, 2015, 16(2): 187-199. DOI: 10.1016/S14702045(14)71207-0. ［31］ Doyen J, Poudenx M, Gal J, et al. Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: a TITE-CRM phase 1 trial［J］. Radiother Oncol, 2018, 127(2): 239-245. DOI: 10.1016/j.radonc.2018.03.024. ［32］ Hechtner M, Krause M, König J, et al. Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy-results of the randomized CHARTWEL trial［J］. Radiother Oncol, 2018, 126(2): 283-290. DOI: 10.1016/j.radonc.2017.12.005. ［33］ De Ruysscher D, Dingemans AC, Praag J, et al. Prophylactic cranial irradiation versus observation in radically treated stage Ⅲ non-small-cell lung cancer: a randomized phase Ⅲ NVALT-11/DLCRG-02 study［J］. J Clin Oncol, 2018, 36(23): 2366-2377. DOI: 10.1200/JCO.2017.77.5817. ［34］ Sun A, Hu C, Wong SJ, et al. Prophylactic cranial irradiation vs observation in patients with locally advanced non-small cell lung cancer: a long-term update of the NRG oncology/RTOG 0214 phase 3 randomized clinical trial［J］. JAMA Oncol, 2019. DOI: 10.1001/jamaoncol.2018.7220. ［35］ Palma DA, Olson RA, Harrow S, et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial［J］. Int J Radiat Oncol Biol Phys, 2018, 102(3 Suppl): S3-S4. ［36］ Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial［J］. JAMA Oncol, 2018, 4(1): e173501. DOI: 10.1001/jamaoncol.2017.3501. ［37］ Gerber DE. Maintenance therapy for advanced lung cancer: who, what, and when?［J］. J Clin Oncol, 2013, 31(24): 2983-2990. DOI: 10.1200/jco.2012.48.5201. ［38］ Petty WJ, Urbanic JJ, Ahmed T, et al. Long-term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2018, 102(3): 527-535. DOI: 10.1016/j.ijrobp.2018.06.400. ［39］ Xu Q, Zhou F, Liu H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs［J］. J Thorac Oncol, 2018, 13(9): 1383-1392. DOI: 10.1016/j.jtho.2018.05.019. ［40］ Elamin YY, Gomez DR, Antonoff MB, et al. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC)［J］. Clin Lung Cancer, 2019, 20(1): 43-47. DOI: 10.1016/j.cllc.2018.09.015.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[4]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[5]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[6]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[7]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[8]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[9]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[10]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[11]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[12]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[13]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[14]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[15]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.